Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease

The low response to vaccines is a well-known problem in cirrhosis. We evaluated the safety and immunogenicity of booster doses in patients with chronic liver disease (CLD), comparing the humoral response in cirrhotic vs. non-cirrhotic patients, and the impact of different factors on immune response....

Descripción completa

Detalles Bibliográficos
Autores principales: Cossiga, Valentina, Capasso, Mario, Guarino, Maria, Loperto, Ilaria, Brusa, Stefano, Cutolo, Francesco Maria, Attanasio, Maria Rosaria, Lieto, Raffaele, Portella, Giuseppe, Morisco, Filomena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056762/
https://www.ncbi.nlm.nih.gov/pubmed/36983282
http://dx.doi.org/10.3390/jcm12062281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056762/
https://www.ncbi.nlm.nih.gov/pubmed/36983282
http://dx.doi.org/10.3390/jcm12062281

Ejemplares similares